MCV as a guide to phlebotomy therapy for hemochromatosis

Transfusion

Volumn 41, Issue 6, 2001, Pages 819-827

  Bolan, Charles D ^a   Conry Cantilena, Cathy ^a   Mason, Glorice ^a   Rouault, Tracey A ^a   Leitman, Susan F ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOCHROMATOSIS; HEMOGLOBIN DETERMINATION; HUMAN; IRON STORAGE; MAINTENANCE THERAPY; MALE; MEAN CORPUSCULAR VOLUME; PHLEBOTOMY; PRACTICE GUIDELINE; RETICULOCYTOSIS; TRANSFERRIN BLOOD LEVEL;

ADULT; AGED; ERYTHROCYTE INDICES; FEMALE; HEMOCHROMATOSIS; HUMANS; MALE; MIDDLE AGED; PHLEBOTOMY; PREDICTIVE VALUE OF TESTS;

EID: 0034974248     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41060819.x     Document Type: Article

References (65)

1. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
2. Celtic origin of the C282Y mutation of hemochromatosis
3. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression
4. A population-based study of the clinical expression of the hemochromatosis gene
5. Iron is hot: An update on the pathophysiology of hemochromatosis
6. The rate of iron accumulation in iron storage disease
7. Intestinal mucosal uptake of iron and iron retention in idiopathic haemochromatosis as evidence for a mucosal abnormality
8. Iron kinetics with emphasis on iron overload
9. Model of reticuloendothelial iron metabolism in humans: Abnormal behavior in idiopathic hemochromatosis and in inflammation
10. Iron release from human monocytes after erythrophagocytosis in vitro: An investigation in normal subjects and hereditary hemochromatosis patients
11. A history of phlebotomy therapy for hemochromatosis
12. Disorders of iron metabolism
13. Screening for hemochromatosis
14. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis
15. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis
16. Diagnosis and management of hemochromatosis
17. Management of hemochromatosis
18. Pathogenesis and management of haemochromatosis
19. Hereditary haemochromatosis: Diagnosis and management in the gene era
20. Nonequivalence of automated and manual hematocrit and erythrocytic indices
21. Examination of the blood and bone marrow
22. Transferrin index: An alternative method for calculating the iron saturation of transferrin
23. Hemochromatosis and arthritis
24. Hemochromatosis arthropathy
25. The natural history of iron deficiency induced by phlebotomy
26. Management of familial hemochromatosis
27. Histogenesis of the hepatic lesion in primary hemochromatosis: With consideration of the pseudo-iron deficient state produced by phlebotomies
28. The differential ferrioxamine test in the management of idiopathic haemochromatosis
29. Idiopathic hemochromatosis, an iron storage disease
30. Hereditary hemochromatosis: Etiologic, pathologic, and clinical aspects
31. Iron metabolism during treatment of idiopathic hemochromatosis
32. Long term results of venesection therapy in idiopathic haemochromatosis
33. Idiopathic hemochromatosis, an interim report
34. Homozygosity for hemochromatosis: Clinical manifestations
35. Iron overload
36. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy
37. Advances in the diagnosis and management of hereditary hemochromatosis
38. Iron, atherosclerosis, and ischemic heart disease
39. The iron hypothesis: Does iron play a role in atherosclerosis?
40. Iron, friend or foe? "Freedom" makes the difference
41. New developments in hereditary hemochromatosis
42. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis
43. HFE genotype in patients with hemochromatosis and other liver diseases
44. Function and regulation of transferrin and ferritin
45. Normal serum ferritin concentrations in precirrhotic hemochromatosis
46. Transferrin iron, chelatable iron and ferritin in idiopathic haemochromatosis
47. Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes
48. Transient hepatic deposition of iron in primary hemochromatosis with iron deficiency following venesection
49. A study of internal distribution of iron in man
50. Screening for hemochromatosis in primary care settings
51. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation
52. Peripheral blood erythrocyte parameters in hemochromatosis: Evidence for increased erythrocyte hemoglobin content
53. Serum transferrin receptor: A quantitative measure of tissue iron deficiency
54. Marrow radioiron kinetics
55. Hypochromic red blood cells and reticulocytes
56. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis
57. Regulators of iron balance in humans
58. The absorption of radio-iron labeled foods and iron salts in normal and iron-deficient subjects and in idiopathic hemochromatosis
59. Blood from patients with hereditary hemochromatosis - A wasted resource